Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

More fastest-growing drugs. Amgen will be prohibited from bundling any of its products with Tepezza or Krystexxa—Horizon’s medications for thyroid eye disease and chronic refractory gout, ...

The other issue on Amgen investors’ minds is the fact that Trump said tariffs on pharmaceutical products are likely coming, further pressuring Amgen’s earnings multiple. But that likely makes ...

Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but the firm has expanded its portfolio to include innovative drugs in therapeutic areas ranging ...

Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but it has expanded its portfolio to include innovative drugs in therapeutic areas ranging from ...

The shortfall for the Horizon products came during a quarter in which most of the company’s other treatments exceeded expectations. In fact, Amgen’s overall revenue of $8.1 billion was a 9% ...

The pact also dismisses the antitrust claims of six states that joined the FTC in May seeking to block the deal over concerns that Amgen would illegally bundle its products with Horizon’s ...

By comparison, current market leaders Eli Lilly (LLY) and Novo Nordisk (NVO) have products that provide weight loss between 14% and 24%. Analysts on an investor call with Amgen Tuesday morning ...

Amgen's top-selling products include the osteoporosis treatment Prolia and the rheumatoid arthritis drug Enbrel. The IRS accused Amgen of underreporting taxes from 2010 to 2015, mainly for ...

The FTC’s concern was that, by acquiring these products, Amgen would stifle competition by making it harder for consumers to have access to cheaper medicines if they were developed by competitors.